Finance News World

Epilepsy Pipeline, Emerging Therapies, Key Pharma Players, Clinical Trials, Growth Prospects, and Treatment Landscape | DelveInsight

 Breaking News
  • No posts were found

Epilepsy Pipeline, Emerging Therapies, Key Pharma Players, Clinical Trials, Growth Prospects, and Treatment Landscape | DelveInsight

January 12
18:02 2022
Epilepsy Pipeline, Emerging Therapies, Key Pharma Players, Clinical Trials, Growth Prospects, and Treatment Landscape | DelveInsight
Epilepsy Pipeline

The Epilepsy Pipeline landscape is evolving with increased insight into biological pathways and mechanisms underlying Epilepsy, leading towards more targeted therapies.

DelveInsight’s Epilepsy Pipeline Insight 2021 report offers exhaustive global coverage of available, marketed, and pipeline therapies under different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Epilepsy pipeline domain. 

 

Some of the essential takeaways from the Epilepsy Pipeline report:

  • DelveInsight’s Epilepsy Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies. 
  • Major pharmaceutical companies are developing potential drug candidates to improve the Epilepsy treatment scenario, such as Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
  • Key Epilepsy pipeline therapies such as OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others are under investigation in different phases of clinical trials.
  • In January 2021, Addex Therapeutics announced that its partner Janssen Pharmaceuticals had received FDA’s Investigational New Drug (IND) approval to begin a Phase IIa proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with Epilepsy.
  • In October 2020, PTC Therapeutics announced the initiation of a registration-directed Phase II/III clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial Epilepsy, the highly morbid condition of refractory seizures in children with inherited mitochondrial disease.

 

Request for Epilepsy sample report to learn more about trends in specific geographies @ Epilepsy Emerging Therapies and Forecast

 

The Epilepsy pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Epilepsy products, comprehensive assessment of driving and restraining factors, and opportunities as well as risks in the Epilepsy pipeline landscape.

 

Epilepsy Overview

Epilepsy is a chronic neurological disorder characterized by frequent and recurring seizures leading to unusual behavior. The primary cause of Epilepsy is not clear, but it is noted that any change in the nerve cells, neurons, and the brain resulting in abnormal signals can be the possible reason.

The most common symptom of Epilepsy includes seizures; however, additional symptoms like convulsion without fever, low consciousness, less awareness, loss of taste, smell, sight, hearing, etc., can also be present.

 

For further information about Epilepsy treatment and pipeline therapies, visit @ Epilepsy Pipeline Assessment

 

Epilepsy Pipeline Drugs

Drug

Company

Phase

MoA

RoA

OPC-214870 

Otsuka Pharmaceutical Co. Ltd 

Phase I

Antiepileptic

Oral

CT-010

Cerebral Therapeutics LLC

Phase II

4-aminobutyrate transaminase inhibitors

Intraventricular

Ganaxolone

Marinus Pharmaceuticals

Phase III

GABA A receptor agonists

Intravenous

XEN496

Xenon Pharmaceuticals

Phase III

KCNQ potassium channel agonists

Oral

Vatiquinone 

PTC Therapeutics

Phase II/III

NQO1 modulators

Oral

E-2730

Eisai

Phase II

Synaptic transmission modulators

Oral

NBI 827104

Neurocrine Biosciences

Phase II

T type calcium channel antagonists

Oral

 

Epilepsy Therapeutics Assessment

The Epilepsy Pipeline report proffers an integral view of the Epilepsy emerging novel therapies segregated by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.

By Product Type

  • Mono
  • Combination
  • Mono/Combination

By Stage

  • Discovery 
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Route of Administration

  • Subcutaneous
  • Intravenous
  • Oral
  • Intraventricular
  • Inhalation

By Molecule Type 

  • Gene therapy
  • Stem cell therapy
  • Small molecules
  • Pyridines

By Mechanism of Action

  • 4-aminobutyrate transaminase inhibitors
  • GABA A receptor agonists
  • KCNQ potassium channel agonists
  • NQO1 modulators
  • Serotonin receptor agonists
  • T type calcium channel antagonists

By Targets

  • GABA A receptor
  • KCNQ potassium channel
  • Serotonin receptor
  • NQO1
  • T type calcium channel 
  • Synaptic transmission

 

Dive deep into rich insights of Epilepsy novel and emerging drugs and their analysis @ Epilepsy Pipeline Emerging Novel Therapies 

 

Scope of the Epilepsy Pipeline Report 

  • Coverage: Global 
  • Major Players: Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
  • Key Epilepsy Pipeline Therapies: OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others.

 

Table of Contents 

1

Introduction

2

Executive Summary

3

Epilepsy: Overview

4

Epilepsy – Analytical Perspective In-depth Commercial Assessment

5

Pipeline Therapeutics

6

Late Stage Products (Phase III)

7

Late Stage Products (Phase II/III)

8

Mid Stage Products (Phase II)

9

Early Stage Products (Phase I)

10

Therapeutic Assessment

11

Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Epilepsy Key Companies

14

Epilepsy Key Products

15

Epilepsy- Unmet Needs

16

Epilepsy- Market Drivers and Barriers

17

Epilepsy- Future Perspectives and Conclusion

18

Epilepsy Analyst Views

19

Appendix

20

About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit https://www.delveinisght.com/blog/

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/epilepsy-pipeline-insight